Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:50866 |
Name | oral squamous cell carcinoma |
Definition | An oral cavity cancer that has_material_basis_in squamous cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer oral cavity cancer oral squamous cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Plicamycin | oral squamous cell carcinoma | not applicable | detail... |
Unknown unknown | Temsirolimus | oral squamous cell carcinoma | not applicable | detail... |
Unknown unknown | TAE226 | oral squamous cell carcinoma | not applicable | detail... |
Unknown unknown | Everolimus | oral squamous cell carcinoma | not applicable | detail... |
Unknown unknown | Cisplatin + Olaparib | oral squamous cell carcinoma | not applicable | detail... |
Unknown unknown | Trametinib | oral squamous cell carcinoma | not applicable | detail... |
Unknown unknown | Palbociclib | oral squamous cell carcinoma | not applicable | detail... |
PIK3CA H1047R | Palbociclib | oral squamous cell carcinoma | resistant | detail... |
PIK3CA H1047R | Ribociclib | oral squamous cell carcinoma | decreased response | detail... |
PIK3CA H1047R | Abemaciclib | oral squamous cell carcinoma | decreased response | detail... |
PIK3CA H1047L | Palbociclib + PF-04691502 | oral squamous cell carcinoma | sensitive | detail... |
PIK3CA H1047L | PF-04691502 | oral squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA H1047L | Palbociclib | oral squamous cell carcinoma | decreased response | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00904345 | Phase II | Cetuximab | Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) | Terminated | USA | 0 |
NCT01195922 | Phase Ib/II | Sirolimus | Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
NCT01540682 | Phase I | Alisertib + Cetuximab | MLN8237 in Head and Neck Cancer | Completed | USA | 0 |
NCT01553851 | Phase II | Trametinib | GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer | Completed | USA | 0 |
NCT01612351 | Phase II | Carboplatin + Cisplatin + Lapatinib + Paclitaxel Carboplatin + Lapatinib + Paclitaxel | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery | Active, not recruiting | USA | 0 |
NCT01732640 | Phase Ib/II | Afatinib + Carboplatin + Paclitaxel Cisplatin | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. | Terminated | USA | 0 |
NCT01783587 | Phase I | Afatinib Docetaxel | Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer | Completed | USA | 0 |
NCT01810913 | Phase II | Docetaxel Cisplatin Cetuximab + Docetaxel | Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer | Recruiting | USA | CAN | 1 |
NCT01824823 | Phase II | Afatinib | Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence | Terminated | USA | 0 |
NCT01914900 | Phase II | Cisplatin + Docetaxel + Fluorouracil | Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer | Completed | 1 | |
NCT01927744 | Phase II | Docetaxel + Erlotinib Cisplatin Docetaxel Carboplatin | Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection | Active, not recruiting | USA | 0 |
NCT02196168 | Phase II | Adavosertib Cisplatin | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Terminated | CAN | 0 |
NCT02289209 | Phase II | Pembrolizumab | Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck | Recruiting | USA | 0 |
NCT02296684 | Phase II | Pembrolizumab Cisplatin | Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT02334319 | Phase I | Ganetespib | Ganetespib Window of Opportunity Study in Head and Neck Cancers | Terminated | USA | 0 |
NCT02358031 | Phase III | Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin | A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) | Active, not recruiting | 0 | |
NCT02381535 | Phase I | Cisplatin Onalespib | Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin | Active, not recruiting | USA | CAN | 0 |
NCT02454179 | Phase II | Pembrolizumab Acalabrutinib | Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
NCT02473731 | Phase I | CDX-3379 | A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients | Completed | USA | 0 |
NCT02499120 | Phase II | Palbociclib Cetuximab | Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer | Active, not recruiting | USA | 14 |
NCT02499328 | Phase Ib/II | AZD9150 + Durvalumab AZD5069 + Durvalumab Durvalumab AZD9150 | Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck | Active, not recruiting | USA | 5 |
NCT02551159 | Phase III | Cisplatin Durvalumab Carboplatin + Cetuximab + Fluorouracil Tremelimumab | Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN | Active, not recruiting | USA | CAN | 21 |
NCT02585973 | Phase I | Adavosertib + Cisplatin | Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC | Completed | USA | 0 |
NCT02586207 | Phase I | Cisplatin + Pembrolizumab | Pembrolizumab in Combination With CRT for LA-SCCHN | Active, not recruiting | USA | 0 |
NCT02734537 | Phase II | Cisplatin | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Recruiting | USA | 0 |
NCT02741570 | Phase III | Carboplatin + Cetuximab + Cisplatin + Fluorouracil Ipilimumab + Nivolumab | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Active, not recruiting | USA | 17 |
NCT02764593 | Phase I | Nivolumab Cisplatin + Nivolumab Cetuximab + Nivolumab | Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT02769520 | Phase II | Pembrolizumab | Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck | Recruiting | USA | 0 |
NCT02775812 | Phase I | Cisplatin + Pembrolizumab | Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT02777385 | Phase II | Cisplatin + Pembrolizumab | Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer | Recruiting | USA | 0 |
NCT02827838 | Phase I | Durvalumab | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer | Recruiting | USA | 0 |
NCT02873819 | Phase II | MAGE-A3 vaccine Cyclophosphamide + Poly ICLC + Sargramostim | Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity | Active, not recruiting | USA | 6 |
NCT02892201 | Phase II | Pembrolizumab | Pembrolizumab in HNSCC With Residual Disease After Radiation | Active, not recruiting | USA | 0 |
NCT02919683 | Phase II | Nivolumab Ipilimumab + Nivolumab | Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity | Active, not recruiting | USA | 0 |
NCT02993991 | Phase I | Durvalumab + Mocetinostat | Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity | Withdrawn | CAN | 0 |
NCT02994069 | Phase II | Cisplatin | Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers | Recruiting | USA | 0 |
NCT03021993 | Phase II | Nivolumab | Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer | Active, not recruiting | USA | 0 |
NCT03162731 | Phase I | Ipilimumab + Nivolumab | Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer | Active, not recruiting | USA | 0 |
NCT03238365 | Phase I | Nivolumab + Tadalafil Nivolumab | Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03247309 | Phase I | Aldesleukin + IMA201 Cyclophosphamide + Fludarabine | TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) | Recruiting | USA | 0 |
NCT03258008 | Phase II | ISA101b + Utomilumab | Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer | Active, not recruiting | USA | 0 |
NCT03341936 | Phase II | Lirilumab + Nivolumab | Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck | Completed | USA | 0 |
NCT03342352 | Phase III | Carboplatin + Cetuximab + Cisplatin + Fluorouracil Carboplatin + Cisplatin + Epacadostat + Fluorouracil + Nivolumab Carboplatin + Cisplatin + Fluorouracil + Nivolumab | Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) | Withdrawn | 0 | |
NCT03342911 | Phase II | Carboplatin + Nivolumab + Paclitaxel | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | Suspended | USA | 0 |
NCT03349710 | Phase III | Cetuximab Cisplatin Cetuximab + Nivolumab Cisplatin + Nivolumab | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | Completed | USA | 9 |
NCT03370276 | Phase Ib/II | Cetuximab + Nivolumab | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03381183 | Phase Ib/II | Cyclophosphamide + Durvalumab + Tremelimumab | IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT03383094 | Phase II | Pembrolizumab Cisplatin + Radiotherapy | Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | Recruiting | USA | 0 |
NCT03386838 | Phase III | BMS-986205 + Nivolumab Carboplatin + Cetuximab + Cisplatin + Fluorouracil | An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck | Withdrawn | USA | 0 |
NCT03515538 | Phase II | Cisplatin + RRx-001 RRx-001 | Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers | Completed | USA | 0 |
NCT03524326 | Phase I | Cetuximab + Lenvatinib | Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT03575234 | Phase Ib/II | Cyclophosphamide + IRX-2 + Nivolumab | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer | Withdrawn | USA | 0 |
NCT03575598 | Phase I | MGCD516 + Nivolumab | Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study | Recruiting | CAN | 0 |
NCT03618134 | Phase Ib/II | Durvalumab Durvalumab + Tremelimumab | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | Recruiting | USA | 0 |
NCT03625323 | Phase II | Eftilagimod alpha + Pembrolizumab | Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002) | Recruiting | USA | 3 |
NCT03635164 | Phase I | Durvalumab | Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT03719690 | Phase II | Tipifarnib | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN) | Recruiting | USA | 15 |
NCT03818542 | Phase I | ABBV-927 ABBV-368 ABBV-181 | A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma | Terminated | USA | 0 |
NCT03821935 | Phase I | ABBV-151 ABBV-151 + ABBV-181 | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 9 |
NCT03829722 | Phase II | Carboplatin + Nivolumab + Paclitaxel | Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | Recruiting | USA | 0 |
NCT03865082 | Phase II | IMO-2125 + Ipilimumab + Nivolumab | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | Recruiting | USA | 0 |
NCT03906526 | Phase I | Motolimod Motolimod + Nivolumab Nivolumab | A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer | Recruiting | USA | 0 |
NCT03944915 | Phase II | Carboplatin + Nivolumab + Paclitaxel Cisplatin + Filgrastim + Fluorouracil + Hydroxyurea + Paclitaxel | De-Escalation Therapy for Human Papillomavirus Negative Disease (DEPEND) | Recruiting | USA | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04106362 | Phase II | Cisplatin Cetuximab + Cisplatin | Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT04183166 | Phase I | TG4050 | A Clinical Trial Evaluating TG4050 in Head and Neck Cancer | Recruiting | USA | 2 |
NCT04193293 | Phase Ib/II | Duvelisib + Pembrolizumab | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | Recruiting | USA | 0 |
NCT04196283 | Phase I | ABBV-368 + IMO-2125 ABBV-368 + IMO-2125 + Nab-paclitaxel ABBV-181 + ABBV-368 + IMO-2125 + Nab-paclitaxel | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 5 |
NCT04199104 | Phase III | Lenvatinib + Pembrolizumab Pembrolizumab | A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010) (LEAP-10) | Recruiting | USA | CAN | 17 |
NCT04290546 | Phase I | ALT-803 + CIML-NK cells + Ipilimumab ALT-803 + CIML-NK cells | CIML NK Cell in Head & Neck Cancer | Recruiting | USA | 0 |
NCT04363242 | Phase I | SYN125 SYN004 + SYN125 | A Study to Find the Maximum Tolerated Dose of SYN125 in People With Advanced Colorectal and Head and Neck Cancer | Recruiting | USA | 0 |
NCT04453046 | Phase I | Pembrolizumab | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | Recruiting | USA | 0 |
NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Recruiting | USA | CAN | 5 |
NCT04588038 | Phase I | NT-I7 | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery | Not yet recruiting | USA | 0 |
NCT04624113 | Phase Ib/II | Pembrolizumab + Tazemetostat | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | Not yet recruiting | USA | 0 |
NCT04633278 | Phase II | Pembrolizumab + QbG10 | CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT04643379 | Phase II | Carboplatin + Olaparib + Pembrolizumab Olaparib + Pembrolizumab | Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | Not yet recruiting | USA | 0 |
NCT04665843 | Phase II | Atezolizumab + MTIG7192A Atezolizumab | A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (SKYSCRAPER-09) | Not yet recruiting | USA | 12 |
NCT04671667 | Phase II | Cisplatin Pembrolizumab Carboplatin | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT04722523 | Phase I | Cemiplimab + Cetuximab + Cisplatin + Docetaxel Carboplatin + Cemiplimab + Cetuximab + Docetaxel | A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer | Recruiting | USA | 0 |
NCT04754321 | Phase I | Pembrolizumab | Pembrolizumab and Radiation Therapy Before and During Surgery for the Treatment of Persistent or Recurrent Head and Neck Cancer | Not yet recruiting | USA | 0 |